Furthermore, many studies fail to account for concurrent medications like corticosteroids, which could independently affect COVID-19 outcomes, and offer limited discussion on biologics’ interactions with SARS-CoV-2 pathophysiology—such as ACE2 and TMPRSS2 modulation—weakening the mechanistic rationale. This evidence concerns the gene ACE2 and COVID-19.